Avantax Advisory Services Inc. Raises Holdings in Qiagen N.V. (NYSE:QGEN)

Avantax Advisory Services Inc. boosted its position in Qiagen N.V. (NYSE:QGEN) by 30.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,869 shares of the company’s stock after acquiring an additional 2,290 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Qiagen were worth $396,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Qiagen in the 4th quarter valued at about $202,000. Wells Fargo & Company MN raised its holdings in Qiagen by 31.8% in the fourth quarter. Wells Fargo & Company MN now owns 66,779 shares of the company’s stock valued at $2,974,000 after buying an additional 16,106 shares during the period. GAMMA Investing LLC lifted its position in Qiagen by 93.9% during the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock valued at $118,000 after buying an additional 1,425 shares in the last quarter. LPL Financial LLC grew its stake in Qiagen by 2.6% during the fourth quarter. LPL Financial LLC now owns 17,240 shares of the company’s stock worth $768,000 after buying an additional 432 shares during the period. Finally, Ameriprise Financial Inc. increased its position in shares of Qiagen by 66.3% in the fourth quarter. Ameriprise Financial Inc. now owns 63,026 shares of the company’s stock worth $2,807,000 after acquiring an additional 25,134 shares in the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Trading Down 5.0%

Shares of NYSE:QGEN opened at $47.47 on Thursday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.83 and a current ratio of 3.37. The stock has a market capitalization of $10.55 billion, a price-to-earnings ratio of 28.05, a PEG ratio of 2.54 and a beta of 0.64. Qiagen N.V. has a 1-year low of $37.63 and a 1-year high of $51.88. The company has a 50 day moving average price of $47.89 and a 200 day moving average price of $43.53.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting the consensus estimate of $0.60. The business had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. Qiagen had a return on equity of 14.77% and a net margin of 18.30%. The company’s revenue was up 7.7% compared to the same quarter last year. During the same period last year, the company posted $0.55 EPS. On average, research analysts anticipate that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Qiagen Announces Dividend

The business also recently disclosed a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were issued a dividend of $0.25 per share. This represents a yield of 52.0%. The ex-dividend date was Wednesday, July 2nd. Qiagen’s payout ratio is presently 62.50%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Barclays initiated coverage on shares of Qiagen in a report on Tuesday, June 24th. They set an “overweight” rating and a $55.00 target price on the stock. Wall Street Zen raised Qiagen from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Robert W. Baird increased their target price on Qiagen from $42.00 to $43.00 and gave the company a “neutral” rating in a research note on Monday, April 21st. Finally, Bank of America boosted their price target on Qiagen from $50.00 to $53.00 and gave the stock a “buy” rating in a research report on Thursday, June 26th. Seven investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $49.40.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.